{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:50:49Z","timestamp":1791496249065,"version":"4.3.4"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T00:00:00Z","timestamp":1709942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T00:00:00Z","timestamp":1709942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070604"],"award-info":[{"award-number":["82070604"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270618"],"award-info":[{"award-number":["82270618"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Shanghai Municipal Key Clinical Specialty","award":["shslczdzk01103"],"award-info":[{"award-number":["shslczdzk01103"]}]},{"name":"the Shanghai Ruijin Hospital Three-Year Plan of the Clinical Skills and Innovations","award":["2018CR005"],"award-info":[{"award-number":["2018CR005"]}]},{"name":"the Shanghai Three-year public health plan","award":["GWV-10.1-XK13"],"award-info":[{"award-number":["GWV-10.1-XK13"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background and aims<\/jats:title>\n                <jats:p>The identification of reliable predictors for hepatitis B surface antigen (HBsAg) seroclearance remains controversial. We aimed to summarize potential predictors for HBsAg seroclearance by pegylated interferon-\u03b1 (PegIFN\u03b1) in patients with chronic HBV infection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A systematic search of the Cochrane Library, Embase, PubMed, and Web of Science databases was conducted from their inception to 28 September 2022. Meta-analyses were performed following the PRISMA statement. Predictors of HBsAg seroclearance were evaluated based on baseline characteristics and on-treatment indicators.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>This meta-analysis encompasses 27 studies, including a total of 7913 patients. The findings reveal several factors independently associated with HBsAg seroclearance induced by PegIFN\u03b1-based regimens. These factors include age (OR\u2009=\u20090.961), gender (male vs. female, OR\u2009=\u20090.537), genotype (A vs. B\/D; OR\u2009=\u20097.472, OR\u2009=\u200910.738), treatment strategy (combination vs. monotherapy, OR\u2009=\u20092.126), baseline HBV DNA (OR\u2009=\u20090.414), baseline HBsAg (OR\u2009=\u20090.373), HBsAg levels at week 12 and 24 (OR\u2009=\u20090.384, OR\u2009=\u20090.294), HBsAg decline from baseline to week 12 and 24 (OR\u2009=\u20096.689, OR\u2009=\u20096.513), HBsAg decline from baseline\u2009\u2265\u20091 log<jats:sub>10<\/jats:sub> IU\/ml and\u2009\u2265\u20090.5 log<jats:sub>10<\/jats:sub> IU\/ml at week 12 (OR\u2009=\u200918.277; OR\u2009=\u20094.530), and ALT elevation at week 12 (OR\u2009=\u20093.622). Notably, subgroup analysis suggests no statistical association between HBsAg levels at week 12 and HBsAg seroclearance for treatment duration exceeding 48\u00a0weeks. The remaining results were consistent with the overall analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This is the first meta-analysis to identify predictors of HBsAg seroclearance with PegIFN\u03b1-based regimens, including baseline and on-treatment factors, which is valuable in developing a better integrated predictive model for HBsAg seroclearance to guide individualized treatment and achieve the highest cost-effectiveness of PegIFN\u03b1.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12072-024-10648-8","type":"journal-article","created":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T17:01:33Z","timestamp":1710003693000},"page":"892-903","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Predictors of HBsAg seroclearance in patients with chronic HBV infection treated with pegylated interferon-\u03b1: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"18","author":[{"given":"Shaowen","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiguang","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2582-8803","authenticated-orcid":false,"given":"Qing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,9]]},"reference":[{"key":"10648_CR1","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","volume":"401","author":"WJ Jeng","year":"2023","unstructured":"Jeng WJ, Papatheodoridis GV, Lok ASF. Hepatitis B. Lancet. 2023;401:1039\u20131052","journal-title":"Lancet"},{"key":"10648_CR2","doi-asserted-by":"publisher","first-page":"e195718","DOI":"10.1001\/jamanetworkopen.2019.5718","volume":"2","author":"C Song","year":"2019","unstructured":"Song C, Lv J, Liu Y, Chen JG, Ge Z, Zhu J, et al. Associations between hepatitis B virus infection and risk of all cancer types. JAMA Netw Open. 2019;2:e195718","journal-title":"JAMA Netw Open"},{"key":"10648_CR3","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S1473-3099(16)30204-3","volume":"16","author":"S Nayagam","year":"2016","unstructured":"Nayagam S, Thursz M, Sicuri E, Conteh L, Wiktor S, Low-Beer D, et al. Requirements for global elimination of hepatitis B: a modelling study. Lancet Infect Dis. 2016;16:1399\u20131408","journal-title":"Lancet Infect Dis"},{"key":"10648_CR4","first-page":"879","volume":"8","author":"CollaboratorS PO","year":"2022","unstructured":"CollaboratorS PO. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. Lancet Gastroenterol Hepatol. 2022;8:879\u2013907","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10648_CR5","doi-asserted-by":"publisher","first-page":"e002306","DOI":"10.1136\/bmjgh-2020-002306","volume":"5","author":"S Chen","year":"2020","unstructured":"Chen S, Mao W, Guo L, Zhang J, Tang S. Combating hepatitis B and C by 2030: achievements, gaps, and options for actions in China. BMJ Glob Health. 2020;5:e002306","journal-title":"BMJ Glob Health"},{"key":"10648_CR6","first-page":"1309","volume":"30","author":"Chinese Medical Association","year":"2022","unstructured":"Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2022). Zhonghua Gan Zang Bing Za Zhi. 2022;30:1309\u20131331","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"67","key":"10648_CR7","first-page":"370","volume":"2017","author":"EASL","year":"2017","unstructured":"EASL. Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;2017(67):370\u2013398","journal-title":"J Hepatol"},{"key":"10648_CR8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","volume":"63","author":"NA Terrault","year":"2016","unstructured":"Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261\u2013283","journal-title":"Hepatology"},{"key":"10648_CR9","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.cgh.2020.05.041","volume":"19","author":"RT Anderson","year":"2021","unstructured":"Anderson RT, Choi HSJ, Lenz O, Peters MG, Janssen HLA, Mishra P, et al. Association between seroclearance of hepatitis B surface antigen and long-term clinical outcomes of patients with chronic hepatitis B virus infection: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021;19:463\u2013472","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10648_CR10","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S2468-1253(18)30308-X","volume":"4","author":"K Zhou","year":"2019","unstructured":"Zhou K, Contag C, Whitaker E, Terrault N. Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses. Lancet Gastroenterol Hepatol. 2019;4:227\u2013238","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10648_CR11","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1080\/14787210.2021.1845652","volume":"19","author":"Y Yang","year":"2021","unstructured":"Yang Y, Huang A, Zhao Y. Spontaneous loss of chronic HBV infection markers in treatment-na\u00efve children: a systematic review and pooled meta-analyses. Expert Rev Anti Infect Ther. 2021;19:649\u2013660","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10648_CR12","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1093\/infdis\/jiab241","volume":"224","author":"YC Hsu","year":"2021","unstructured":"Hsu YC, Yeh ML, Wong GL, Chen CH, Peng CY, Buti M, et al. Incidences and determinants of functional cure during entecavir or tenofovir disoproxil fumarate for chronic hepatitis B. J Infect Dis. 2021;224:1890\u20131899","journal-title":"J Infect Dis"},{"key":"10648_CR13","doi-asserted-by":"publisher","first-page":"7793472021","DOI":"10.3389\/fimmu.2021.779347","volume":"12","author":"A Song","year":"2021","unstructured":"Song A, Lin X, Lu J, Ren S, Cao Z, Zheng S, et al. Pegylated interferon treatment for the effective clearance of hepatitis B surface antigen in inactive HBsAg carriers: a meta-analysis. Front Immunol. 2021;12:7793472021","journal-title":"Front Immunol"},{"key":"10648_CR14","doi-asserted-by":"publisher","first-page":"S860","DOI":"10.1016\/S0168-8278(20)32161-9","volume":"73","author":"D Wu","year":"2020","unstructured":"Wu D, Yan W, Tan DT, Peng SB, Chen Y, Jiang J, et al. Combination of NA, PEG-IFN alpha-2b and GM-CSF enhanced hbsab production in NA experienced CHB patients (the anchor a study): an interim analysis. J Hepatol. 2020;73:S860","journal-title":"J Hepatol"},{"key":"10648_CR15","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1002\/hep.32472","volume":"76","author":"Z Mo","year":"2022","unstructured":"Mo Z, Xie D, Fu L, Zhang W, Wei J, Li G, et al. Functional cure based on pegylated interferon \u0251-2b therapy in nucleoside analog-suppressed HBeAg negative chronic hepatitis B: a multicenter real-world study (Everest Project in China)-4 years data update. Hepatology. 2022;76:S24\u2013S25","journal-title":"Hepatology"},{"key":"10648_CR16","doi-asserted-by":"publisher","first-page":"S844","DOI":"10.1016\/S0168-8278(22)01984-5","volume":"77","author":"XY Chen","year":"2022","unstructured":"Chen XY, Ren S, Lu JF, Ma LN, Zheng SJ, Hu ZJ. Combination therapy in HBeAg-negative chronic hepatitis B patients with low-level viremia to nucleos (tide) analogues. J Hepatol. 2022;77:S844\u2013S844","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"10648_CR17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/jvh.13154","volume":"26","author":"Y Liu","year":"2019","unstructured":"Liu Y, Li H, Yan X, Wei J. Long-term efficacy and safety of peginterferon in the treatment of children with HBeAg-positive chronic hepatitis B. J Viral Hepat. 2019;26(Suppl 1):69\u201376","journal-title":"J Viral Hepat"},{"issue":"Suppl 1","key":"10648_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/jvh.13165","volume":"26","author":"H Fan","year":"2019","unstructured":"Fan H, Lin L, Jia S, Xie M, Luo C, Tan X, et al. Interferon alpha treatment leads to a high rate of hepatitis B surface antigen seroconversion in Chinese children with chronic hepatitis B. J Viral Hepat. 2019;26(Suppl 1):77\u201384","journal-title":"J Viral Hepat"},{"key":"10648_CR19","first-page":"527A","volume":"74","author":"GR Han","year":"2021","unstructured":"Han GR, Zhou GL, Chen C, Wang CX. Efficacy of pegylated interferon alpha-2b therapy in nucleos(t)ide analogue-treated HBV postpartum women: an exploratory study. Hepatology. 2021;74:527A","journal-title":"Hepatology"},{"key":"10648_CR20","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.clinthera.2020.12.022","volume":"43","author":"C Hu","year":"2021","unstructured":"Hu C, Song Y, Tang C, Li M, Liu J, Liu J, et al. Effect of pegylated interferon plus tenofovir combination on higher hepatitis B surface antigen loss in treatment-naive patients with hepatitis B e antigen -positive chronic hepatitis B: a real-world experience. Clin Ther. 2021;43:572\u2013581.e573","journal-title":"Clin Ther"},{"key":"10648_CR21","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1007\/s12072-020-10099-x","volume":"14","author":"J Liu","year":"2020","unstructured":"Liu J, Wang T, Zhang W, Cheng Y, He Q, Wang FS. Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis. Hepatol Int. 2020;14:958\u2013972","journal-title":"Hepatol Int"},{"key":"10648_CR22","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s12250-020-00290-7","volume":"36","author":"M Li","year":"2021","unstructured":"Li M, Zhang L, Lu Y, Chen Q, Lu H, Sun F, et al. Early serum HBsAg kinetics as predictor of HBsAg loss in patients with HBeAg-negative chronic hepatitis B after treatment with pegylated interferon\u03b1-2a. Virol Sin. 2021;36:311\u2013320","journal-title":"Virol Sin"},{"key":"10648_CR23","first-page":"9605892022","volume":"13","author":"M Li","year":"2022","unstructured":"Li M, Xie S, Bi X, Sun F, Zeng Z, Deng W, et al. An optimized mode of interferon intermittent therapy help improve HBsAg disappearance in chronic hepatitis B patients. Front Microbiol. 2022;13:9605892022","journal-title":"Front Microbiol"},{"key":"10648_CR24","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.cgh.2019.04.020","volume":"18","author":"Y Wu","year":"2020","unstructured":"Wu Y, Liu Y, Lu J, Cao Z, Jin Y, Ma L, et al. Durability of interferon-induced hepatitis B surface antigen seroclearance. Clin Gastroenterol Hepatol. 2020;18:514\u2013516.e512","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10648_CR25","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/jvh.13471","volume":"28","author":"A Song","year":"2021","unstructured":"Song A, Wang X, Lu J, Jin Y, Ma L, Hu Z, et al. Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: a meta-analysis. J Viral Hepat. 2021;28:601\u2013612","journal-title":"J Viral Hepat"},{"key":"10648_CR26","doi-asserted-by":"publisher","first-page":"105163","DOI":"10.1016\/j.antiviral.2021.105163","volume":"194","author":"P Ren","year":"2021","unstructured":"Ren P, Li H, Huang Y, Jiang J, Guo S, Cao Z, et al. A simple-to-use tool for predicting response to peginterferon in HBV DNA suppressed chronic hepatitis B patients in China. Antiviral Res. 2021;194:105163","journal-title":"Antiviral Res"},{"key":"10648_CR27","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.jhep.2014.05.044","volume":"61","author":"Q Ning","year":"2014","unstructured":"Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J, et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomized open-label trial (OSST trial). J Hepatol. 2014;61:777\u2013784","journal-title":"J Hepatol"},{"key":"10648_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.14218\/JCTH.2017.00072","volume":"6","author":"P Hu","year":"2018","unstructured":"Hu P, Shang J, Zhang WH, Gong GZ, Li YG, Chen XY, et al. HBsAg Loss with Peg-interferon Alfa-2a in hepatitis B patients with partial response to nucleos(t)ide analog: new switch study. J Clin Transl Hepatol. 2018;6:25\u201334","journal-title":"J Clin Transl Hepatol"},{"key":"10648_CR29","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.3748\/wjg.v26.i13.1525","volume":"26","author":"FP Wu","year":"2020","unstructured":"Wu FP, Yang Y, Li M, Liu YX, Li YP, Wang WJ, et al. Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen <= 1500 IU\/mL: an observational study. World J Gastroenterol. 2020;26:1525\u20131539","journal-title":"World J Gastroenterol"},{"key":"10648_CR30","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.ijid.2020.05.041","volume":"96","author":"XL Bao","year":"2020","unstructured":"Bao XL, Guo J, Xiong F, Qu YC, Gao Y, Gu N, et al. Clinical characteristics of chronic hepatitis B cured by peginterferon in combination with nucleotide analogs. Int J Infect Dis. 2020;96:562\u2013566","journal-title":"Int J Infect Dis"},{"key":"10648_CR31","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1007\/s10620-018-5251-9","volume":"63","author":"SH Ahn","year":"2018","unstructured":"Ahn SH, Marcellin P, Ma X, Caruntu FA, Tak WY, Elkhashab M, et al. Hepatitis B surface antigen loss with tenofovir disoproxil fumarate plus peginterferon alfa-2a: week 120 analysis. Dig Dis Sci. 2018;63:3487\u20133497","journal-title":"Dig Dis Sci"},{"key":"10648_CR32","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1002\/hep.29213","volume":"66","author":"Z Cao","year":"2017","unstructured":"Cao Z, Liu Y, Ma L, Lu J, Jin Y, Ren S, et al. A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha. Hepatology. 2017;66:1058\u20131066","journal-title":"Hepatology"},{"key":"10648_CR33","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/hep.32352","volume":"76","author":"R Erken","year":"2022","unstructured":"Erken R, Loukachov V, van Dort K, van den Hurk A, Takkenberg RB, de Niet A, et al. Quantified integrated hepatitis B virus is related to viral activity in patients with chronic hepatitis B. Hepatology. 2022;76:196\u2013206","journal-title":"Hepatology"},{"key":"10648_CR34","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928","journal-title":"BMJ"},{"key":"10648_CR35","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses; 2018"},{"key":"10648_CR36","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73:712\u2013716","journal-title":"ANZ J Surg"},{"key":"10648_CR37","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.jhep.2022.05.014","volume":"77","author":"S Yoo","year":"2022","unstructured":"Yoo S, Kim JY, Lim YS, Han S, Choi J. Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection. J Hepatol. 2022;77:939\u2013946","journal-title":"J Hepatol"},{"key":"10648_CR38","first-page":"1007380","volume":"2023","author":"S Zhang","year":"2023","unstructured":"Zhang S, Wang C, Lu B. Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluation. Lancet Reg Health West Pac. 2023;2023:1007380","journal-title":"Lancet Reg Health West Pac"},{"key":"10648_CR39","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.21037\/atm-21-1666","volume":"9","author":"R Li","year":"2021","unstructured":"Li R, Lin X, Wang JY, Wang X, Lu J, Liu Y, et al. Cost-effectiveness of combination antiviral treatment with extended duration for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B in China. Ann Transl Med. 2021;9:1365","journal-title":"Ann Transl Med"},{"key":"10648_CR40","first-page":"FP13","volume":"2023","author":"QR Zhang","year":"2023","unstructured":"Zhang QR, Sun F, Yu YQ, Sui SL, Zhao TT, Shang J, et al. The functional cure strategies of patients with high HBsAg levels at baseline with interferon therapy (OASIS Project 1.5 year data). APASL 2023;2023:FP13\u201370","journal-title":"APASL"},{"key":"10648_CR41","first-page":"EPB\u2013052","volume":"2023","author":"QR Zhang","year":"2023","unstructured":"Zhang QR, Sun F, Yu YQ, Sui SL, Zhao TT, Guo Y, et al. The fibrosis profile of patients with chronic Hepatitis B (OASIS Project Baseline). APASL 2023;2023:EPB\u2013052","journal-title":"APASL"},{"key":"10648_CR42","first-page":"SAT452","volume":"77","author":"SG Lim","year":"2022","unstructured":"Lim SG, Pojaga C, Janssen H. Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection not on stable nucleos (t)ide analogue therapy: interim results from the randomised phase 2b B-Clear study. EASL. 2022;77:SAT452","journal-title":"EASL"},{"key":"10648_CR43","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","volume":"387","author":"MF Yuen","year":"2022","unstructured":"Yuen MF, Lim SG, Plesniak R, Tsuji K, Janssen HLA, Pojoga C, et al. Efficacy and safety of bepirovirsen in chronic hepatitis B infection. N Engl J Med. 2022;387:1957\u20131968","journal-title":"N Engl J Med"},{"key":"10648_CR44","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1136\/gutjnl-2022-328041","volume":"72","author":"HLA Janssen","year":"2023","unstructured":"Janssen HLA, Hou J, Asselah T, Chan HLY, Zoulim F, Tanaka Y, et al. Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection. Gut. 2023;72:1385\u20131398","journal-title":"Gut"},{"key":"10648_CR45","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1056\/NEJMoa043470","volume":"352","author":"GKK Lau","year":"2005","unstructured":"Lau GKK, Piratvisuth T, Kang XL, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352:2682\u20132695","journal-title":"N Engl J Med"},{"key":"10648_CR46","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJMoa040431","volume":"351","author":"P Marcellin","year":"2004","unstructured":"Marcellin P, Lau GKK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon Alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351:1206\u20131217","journal-title":"N Engl J Med"},{"key":"10648_CR47","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/hep4.1633","volume":"5","author":"M Bazinet","year":"2021","unstructured":"Bazinet M, P\u00e2ntea V, Cebotarescu V, Cojuhari L, Jimbei P, Anderson M, et al. Persistent control of hepatitis B virus and hepatitis delta virus infection following REP 2139-Ca and pegylated interferon therapy in chronic hepatitis B virus\/hepatitis delta virus coinfection. Hepatol Commun. 2021;5:189\u2013202","journal-title":"Hepatol Commun"},{"key":"10648_CR48","first-page":"S19","volume":"76","author":"MF Yuen","year":"2022","unstructured":"Yuen MF, Lim YS, Cloutier D, Thanawala V. Preliminary 48-week safety and efficacy data of VIR-2218 alone and in combination with pegylated interferon alfa in participants with Chronic HBV infection. AASLD. 2022;76:S19\u2013S20","journal-title":"AASLD"},{"key":"10648_CR49","doi-asserted-by":"publisher","first-page":"104492","DOI":"10.1016\/j.meegid.2020.104492","volume":"85","author":"Y Ma","year":"2020","unstructured":"Ma Y, Wang J, Xiong F, Lu J. Extended duration therapy regimens based on Pegylated interferon for chronic hepatitis B patients focusing on hepatitis B surface antigen loss: a systematic review and meta-analysis. Infect Genet Evol. 2020;85:104492","journal-title":"Infect Genet Evol"},{"key":"10648_CR50","doi-asserted-by":"publisher","first-page":"S865","DOI":"10.1016\/S0168-8278(22)02026-8","volume":"77","author":"J Chen","year":"2022","unstructured":"Chen J, Huang Y. Predictors of sustained response in hepatitis B surface antigen-negative patients after peginterferon therapy: an observational study. J Hepatol. 2022;77:S865","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"10648_CR51","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/jvh.13151","volume":"26","author":"MH Li","year":"2019","unstructured":"Li MH, Yi W, Zhang L, Lu Y, Lu HH, Shen G, et al. Predictors of sustained functional cure in hepatitis B envelope antigen-negative patients achieving hepatitis B surface antigen seroclearance with interferon-alpha-based therapy. J Viral Hepat. 2019;26(Suppl 1):32\u201341","journal-title":"J Viral Hepat"},{"key":"10648_CR52","doi-asserted-by":"publisher","first-page":"11203002023","DOI":"10.3389\/fcimb.2023.1120300","volume":"13","author":"Y Guo","year":"2023","unstructured":"Guo Y, Han J, Zhang Y, Jin C, Zhang Y, He J, et al. End-of-treatment anti-HBs levels and HBeAg status identify durability of HBsAg loss after PEG-IFN discontinuation. Front Cell Infect Microbiol. 2023;13:11203002023","journal-title":"Front Cell Infect Microbiol"},{"key":"10648_CR53","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/jvh.13734","volume":"29","author":"N Gao","year":"2022","unstructured":"Gao N, Yu H, Zhang J, Mo Z, Chu J, Xie C, et al. Role of hepatitis B surface antibody in seroreversion of hepatitis B surface antigen in patients achieving hepatitis B surface antigen loss with pegylated interferon-based therapy. J Viral Hepat. 2022;29:899\u2013907","journal-title":"J Viral Hepat"},{"key":"10648_CR54","doi-asserted-by":"publisher","first-page":"845","DOI":"10.2147\/IDR.S195144","volume":"12","author":"CX Zheng","year":"2019","unstructured":"Zheng CX, Yan HH, Zeng JY, Cai SH, Wu XL. Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B. Infect Drug Resist. 2019;12:845\u2013854","journal-title":"Infect Drug Resist"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10648-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-024-10648-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10648-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T16:24:49Z","timestamp":1716567889000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-024-10648-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,9]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10648"],"URL":"https:\/\/doi.org\/10.1007\/s12072-024-10648-8","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,9]]},"assertion":[{"value":"7 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Shaowen Jiang, Simin Guo, Yan Huang, YalinYin, Jingwen Feng, Huijuan Zhou, Qing Guo, Weijing Wang, Haiguang Xin, Qing Xie declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This article does not contain any studies with human or animal subjects.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}}]}}